The Association Between Type 2 Diabetes and Bone Microarchitecture Assessed by HR-pQCT.
Abstract
Type 2 diabetic patients generally have higher BMD but greater fracture risk. Exploring their bone microarchitecture might help to explain their bone fragility. We conducted a cross-sectional matched analysis within three prospective cohorts including 477 men and women. Each patient with T2DM was matched for age, sex and BMI with two controls, yielding 159 cases and 318 controls. We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to characterize cortical and trabecular bone microarchitecture. In predefined subgroup analyses within T2DM, we compared bone parameters according to glucose-lowering treatment, including metformin-containing regimens versus non-metformin oral regimens and metformin versus insulin-treated patients. In men, femoral neck aBMD was higher in T2DM (0.83 ± 0.13 vs. 0.79 ± 0.14 g/cm2; p < 0.05). Bone size was ~ 5% lower in T2DM-at the tibia in women (623.94 ± 92.42 vs. 656.65 ± 107.09 mm2; p < 0.05) and at the radius in men (386.66 ± 66.71 vs. 407.25 ± 62.53 mm2; p < 0.05). Among women, radial cortical area (44.38 ± 9.55 vs. 41.25 ± 9.94 mm2; p < 0.05) and cortical thickness (0.67 ± 0.16 vs. 0.62 ± 0.17 mm; p < 0.05) were higher in T2DM. Metformin use was associated with higher femoral neck/hip T-scores, and improved cortical microarchitecture-lower cortical porosity at the radius and tibia (p < 0.001 and p = 0.012) and greater tibial cortical thickness/area (p = 0.025/0.009)-compared with other oral therapies. T2DM was…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 477 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.